CN108424469B - 一种芡实种仁多糖及其分离提取方法和用途 - Google Patents
一种芡实种仁多糖及其分离提取方法和用途 Download PDFInfo
- Publication number
- CN108424469B CN108424469B CN201810255095.XA CN201810255095A CN108424469B CN 108424469 B CN108424469 B CN 108424469B CN 201810255095 A CN201810255095 A CN 201810255095A CN 108424469 B CN108424469 B CN 108424469B
- Authority
- CN
- China
- Prior art keywords
- polysaccharide
- semen euryales
- seed kernel
- water
- gordon euryale
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000004676 glycans Chemical class 0.000 title claims abstract description 73
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 73
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 73
- 244000268590 Euryale ferox Species 0.000 title claims abstract description 71
- 235000006487 Euryale ferox Nutrition 0.000 title claims abstract description 68
- 238000000605 extraction Methods 0.000 title claims abstract description 12
- 238000000926 separation method Methods 0.000 title claims abstract description 11
- 235000013399 edible fruits Nutrition 0.000 title claims description 12
- 210000000582 semen Anatomy 0.000 claims abstract description 23
- 239000008103 glucose Substances 0.000 claims abstract description 22
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 17
- 150000002772 monosaccharides Chemical class 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 9
- 229940097043 glucuronic acid Drugs 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 229940079593 drug Drugs 0.000 claims abstract description 8
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 claims abstract description 7
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims abstract description 7
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims abstract description 7
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims abstract description 6
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims abstract description 6
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229930182830 galactose Natural products 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 32
- 239000012153 distilled water Substances 0.000 claims description 15
- 239000006228 supernatant Substances 0.000 claims description 15
- 238000000502 dialysis Methods 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 10
- 238000002390 rotary evaporation Methods 0.000 claims description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 8
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 8
- 239000002244 precipitate Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 230000001603 reducing effect Effects 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 229920005654 Sephadex Polymers 0.000 claims description 3
- 239000012505 Superdex™ Substances 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 230000003544 deproteinization Effects 0.000 claims description 3
- 239000003480 eluent Substances 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 230000014759 maintenance of location Effects 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 3
- 238000003287 bathing Methods 0.000 claims description 2
- 238000010828 elution Methods 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 238000002604 ultrasonography Methods 0.000 claims 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 20
- 102000004877 Insulin Human genes 0.000 abstract description 10
- 108090001061 Insulin Proteins 0.000 abstract description 10
- 229940125396 insulin Drugs 0.000 abstract description 10
- 230000004190 glucose uptake Effects 0.000 abstract description 3
- 230000002218 hypoglycaemic effect Effects 0.000 abstract description 2
- 241000600871 Euryale <brittle star> Species 0.000 abstract 1
- 235000013402 health food Nutrition 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 12
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 8
- 206010022489 Insulin Resistance Diseases 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 210000001789 adipocyte Anatomy 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 238000002329 infrared spectrum Methods 0.000 description 4
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000209477 Nymphaeaceae Species 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- -1 glucose Chemical compound 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000012844 infrared spectroscopy analysis Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- CTYRPMDGLDAWRQ-UHFFFAOYSA-N phenyl hydrogen sulfate Chemical compound OS(=O)(=O)OC1=CC=CC=C1 CTYRPMDGLDAWRQ-UHFFFAOYSA-N 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Sustainable Development (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种芡实种仁多糖及其分离提取方法和用途,其中芡实种仁多糖的分子量为8.75ⅹ103Da,单糖组成及摩尔比为葡萄糖醛酸:甘露糖:葡萄糖:半乳糖:阿拉伯糖=0.55:0.6:52.7:1:4.3。本发明芡实种仁多糖可以促进胰岛素抵抗细胞的葡萄糖摄取量,具有研发降血糖保健食品和药物的应用前景。
Description
技术领域
本发明涉及一种芡实种仁多糖及其分离提取方法和用途,属于天然产物提取和生物活性领域。
背景技术
Ⅱ型糖尿病(T2DM)是一种以高血糖为特征的糖代谢紊乱的疾病。近年来糖尿病患病率迅猛增长,据统计2010年中国糖尿病患病率已高达9.7%,患者人数达到了9240万,预计到2030年将增至1.29亿。因此,T2DM的防治已经成为影响中国公民健康的重要问题之一。糖尿病的主要发病机制是由于胰岛功能缺失或受损引起,既有遗传因素也有环境因素包括后天饮食、作息习惯、肥胖等影响引起胰岛素分泌不足,常常伴有胰岛素抵抗现象发生。
芡实(Eureyale ferox Salisb)是睡莲科(Nymphaeaceae)芡属(Euryale)一年生水生草本植物。野生芡实全国各地分布比较广,人工栽培主要以江苏、浙江和安徽等省为主。芡实成熟种仁含有丰富的基本营养成分,有碳水化合物、蛋白质、矿物质和维生素等,功效成分主要有黄酮类、环肽类、酚类、多糖、甾醇类和脑苷脂等成分。传统中医学上,芡实的成熟种仁具有益肾固精,有健脾利湿作用,常用于治疗遗精遗尿,脾虚久泄,白浊带下。文献调研发现,芡实粗提取物主要有抗氧化、抗心肌缺血、抗衰老、降血糖、降血压及抑菌、保护胃粘膜等作用。然而关于芡实多糖的研究还比较少,只有抗氧化活性方面的报道,目前尚未有芡实种仁多糖结构鉴定及降糖方面的活性报道。
发明内容
本发明提供了一种芡实种仁多糖及其分离提取方法和用途。本发明芡实种仁多糖可以促进胰岛素抵抗细胞的葡萄糖摄取量,天然无毒,具有研发降血糖保健食品和药物的应用前景。
本发明芡实种仁多糖,分子量为8.75ⅹ103Da,单糖组成及摩尔比为葡萄糖醛酸:甘露糖:葡萄糖:半乳糖:阿拉伯糖=0.55:0.6:52.7:1:4.3。本发明芡实种仁多糖的分离提取方法,包括如下步骤:
步骤1:分离提取
将成熟的芡实种仁粉碎成粉末,加入3-5倍体积的蒸馏水超声提取5min,然后于60℃水浴2h,四层纱布过滤,收集上清液,向滤渣中加入蒸馏水重复上述提取过程再次提取,合并上清液;将所得上清液旋蒸浓缩,然后加入四倍体积的无水乙醇4℃下静置沉淀,离心收集沉淀,加水溶解沉淀即得粗多糖水溶液;加水量使沉淀刚好完全溶解即可。
步骤2:sevag法脱蛋白
将步骤1获得的粗多糖水溶液、三氯甲烷和正丁醇按照体积比5:4:1的比例混合,磁力搅拌2-3h,离心后收集上清液;重复上述处理步骤直至蛋白质完全去除,获得脱蛋白芡实种仁多糖溶液;
步骤3:透析除杂
将步骤2获得的脱蛋白芡实种仁多糖溶液旋蒸浓缩除去有机试剂,使用3500KDa的透析袋,流水透析48h,蒸馏水透析24h,再次旋蒸浓缩至浓稠状液体,真空冷冻干燥,即得芡实种仁粗多糖;
步骤4:纯化
将步骤3获得的芡实种仁粗多糖通过SuperdexTM75葡聚糖凝胶柱洗脱分离,以蒸馏水为洗脱液,使用高效液相色谱跟踪检测分离效果,收集保留时间相同的多糖,浓缩冻干后即得芡实种仁纯多糖。
本发明获得的芡实种仁纯多糖的分子量为8.75ⅹ103Da(图1和图2),是一种中性多糖,单糖组成(图3和图4),其单糖组成及摩尔比为葡萄糖醛酸:甘露糖:葡萄糖:半乳糖:阿拉伯糖=0.55:0.6:52.7:1:4.3。红外光谱图显示芡实种仁多糖含有β构型,存在吡喃环,有多糖的五个典型特征峰,如图5。
本发明芡实种仁多糖的的用途,是在制备降血糖保健品或药品中的应用。
本发明以胰岛素抵抗细胞模型为研究对象,研究无毒副作用的芡实种仁多糖的降血糖降血脂效果。
芡实种仁多糖对胰岛素抵抗细胞的葡萄糖摄取的影响实验:
3T3-L1前脂肪细胞诱导分化成熟,使用1μmoL/L的地塞米松诱导48h建立胰岛素抵抗模型后,以不同浓度的芡实种仁纯多糖处理24h,使用葡萄糖检测试剂盒检测细胞上清液中的葡萄糖含量。HepG2细胞也使用同样方法处理。实验结果从图6和图7可知,芡实种仁多糖可以促进胰岛素抵抗细胞的葡萄糖消耗量,改善胰岛素抵抗,具有研制治疗糖尿病药物和保健食品的应用前景。
附图说明
图1是葡聚糖标准曲线。
图2是芡实种仁多糖高效液相色谱图。
图3是标准单糖高效液相色谱图(*-溶剂峰,1-葡萄糖醛酸,2-甘露糖,3-葡萄糖,4-半乳糖,5-阿拉伯糖)。
图4是芡实种仁多糖单糖组成高效液相色谱图(*-溶剂峰,1-葡萄糖醛酸,2-甘露糖,3-葡萄糖,4-半乳糖,5-阿拉伯糖)。
图5是芡实种仁多糖红外光谱图。
图6是芡实种仁多糖对胰岛素抵抗3T3-L1脂肪细胞葡萄糖消耗率的影响,与模型组比较具有显著性差异(*<0.05,**p<0.01,##<0.01)。
图7是芡实种仁多糖对胰岛素抵抗HepG2细胞葡萄糖消耗率的影响,与模型组比较具有显著性差异(*<0.05,**p<0.01,##<0.01)。
具体实施方式
以下通过具体的实施例描述本发明的制备,结构表征及降糖降脂活性,所举实施例只用于解释本发明,并非用于限定本发明的保护范围。
实施例1:芡实种仁多糖的提取和分离纯化
1、分离提取
将成熟的芡实种仁清洗,烘干,粉碎并过40目筛。称取500g芡实种仁粉末,加入2L蒸馏水,搅拌均匀后超声提取5分钟,然后置于60℃水浴锅中水浴,每30min搅拌一次,2h后使用四层纱布过滤,收集上清液,向滤渣中加入2L蒸馏水,重复上述提取过程再次提取,合并上清液;将得到的上清液离心(4000rpm/min,10min),弃沉淀,收集上清液,旋蒸浓缩至150mL,加入4倍体积的无水乙醇在4℃冰箱过夜沉淀,离心(4500rpm/min,10min),收集沉淀,并用尽量少的蒸馏水溶解,再次离心(4500rpm/min,10min),除去水不溶性物质,即得到粗多糖水溶液。
2、sevag法脱蛋白
将步骤1获得的粗多糖水溶液、三氯甲烷和正丁醇按照体积比为5:4:1的比例混合,磁力搅拌2-3h,离心(7500rpm/min,10min),收集上清液;重复上述处理步骤直至蛋白质完全去除,获得脱蛋白芡实种仁多糖溶液。
3、透析除杂
将步骤2获得的脱蛋白芡实种仁多糖溶液旋蒸浓缩除去有机试剂,然后装入截留分子量为3500Da的透析袋中,流动自来水中透析48h,然后在蒸馏水中磁力搅拌透析24h,每4小时换一次蒸馏水,透析完成后取出,旋蒸浓缩至最浓体积,真空冷冻干燥48h,即得芡实粗多糖。
4、纯化
SuperdexTM75葡聚糖凝胶装柱体积为800mm*30mm的柱子,防止有气泡,恒流泵流速为1ml/mim。将步骤3获得的芡实粗多糖用蒸馏水配制成3ml、浓度为50mg/ml的溶液,0.22μm的水相滤头过滤,上样,蒸馏水洗脱,流速为0.68ml/min;3h后,开始收集洗脱液,每管4ml。硫酸苯酚法跟踪检测糖含量,一直收集到不能检测到糖为止。收集的洗脱液,每隔5管,用高效液相色谱检测分离效果,收集保留时间相同的多糖,浓缩冻干后即得芡实种仁纯多糖。使用的色谱柱为UltrahydrogelTM250,规格为7.8*300mm。
实施例2:芡实种仁多糖的结构表征
1、分子量测定
分别精确配制1mg/mL的芡实种仁多糖EFSP-1、T3、T7、T10、T50的溶液1mL,并用0.22μm的微孔过滤膜过滤制样。利用高效液相色谱法检测其出峰时间,上样量为30μL。根据标准品葡聚糖的出峰时间,得出分子量计算公式,并计算芡实种仁多糖的分子量。
2、单糖组成测定
芡实种仁多糖的单糖组成分析采用酸水解-柱前PMP衍生化方法处理样品,再用高效液相色谱法测定。精确称取芡实种仁多糖(10mg)溶于5mL的2moL/L的三氟乙酸(TFA)中,充氮气封管,在110℃油锅水解6h。再用旋转蒸发仪反复旋干,加适量的去离子水,再旋干,如此反复几次直到溶液PH显示中性为止。加入1mL蒸馏水,备用。
标准单糖和已水解的样品溶液中加入50μL,0.5M PMP甲醇溶液和50μL、0.3M NaOH溶液,在70℃的水浴锅中反应30min进行PMP柱前衍生化,然后用50μL的0.3M的HCl中和至中性。所得产物使用高效液相色谱检测,选用DAD检测器。HPLC柱温为30℃,色谱柱为ZorboxEclipse XDB-C18柱(4.6mmⅹ250mm,5μm),在波长为254nm条件下检测。检测流动相选用两种,流动相A为乙酸铵缓冲溶液(200mmoL/L),流动相B为乙腈。时间梯度洗脱0-30min,初始设置为流动相A:流动相B=86%:14%,最终洗脱到比例为流动相A:流动相B=74%:26%,进样量为10μL。
3、红外光谱分析
芡实种仁多糖的红外光谱结构进行分析采用溴化钾压片法,压成薄片,在4000~400cm-1的频率范围内进行测定。称取1mg的芡实种仁多糖,与100mgKBr(1:100)研磨均匀后检测。实验结果:
芡实种仁多糖分子量为8.75ⅹ103Da,共有五种单糖,分别为葡萄糖醛酸、甘露糖、葡萄糖、半乳糖和阿拉伯糖,主要以葡萄糖为主,葡萄糖醛酸、甘露糖含量很少。各种单糖摩尔比为葡萄糖醛酸:甘露糖:葡萄糖:半乳糖:阿拉伯糖=0.55:0.6:52.7:1:4.3。
芡实种仁多糖红外光谱具有五个典型吸收峰,分别是3404cm-1、2921cm-1、1642cm-1、1412cm-1和1032cm-1的位置。在3404cm-1处出现的强而宽的峰是因为醇羟基(O-H)伸缩震动引起的,因存在分子间氢键而出现宽锋;在2921cm-1处出现的中尖峰是饱和烷烃震动区域内,是由C-H伸缩震动产生的。在1642cm-1处的中峰是由O-H的弯曲震动引起的,在1412cm-1处的中峰是由-CH2的变形震动引起的吸收峰。红外光谱看到出现三个峰分别为1153cm-1、1080cm-1和1032cm-1,所以认为存在吡喃环。在900cm-1处出现弱的吸收峰认为此多糖为β构型。
实施例3:芡实种仁多糖的降血糖活性测定
1、芡实种仁多糖对胰岛素抵抗细胞葡萄糖消耗量的影响
3T3-L1脂肪细胞和HepG2细胞使用1μmoL/L的地塞米松作用48h,建立胰岛素抵抗模型后实验分成四组:对照组、模型组(Dex)、阳性对照组(二甲双胍)和芡实多糖EFSP-1组。对照组和模型组使用DMEM高糖完全培养液培养,二甲双胍组使用含有0.5mmoL/L二甲双胍的DMEM高糖完全培养液培养,芡实多糖EFSP-1组由含有不同浓度的芡实多糖EFSP-1(25μg/mL,50μg/mL,100μg/mL,200μg/mL,400μg/mL)DMEM高糖完全培养液培养。药物配成不同浓度等体积,对照组和模型组的培养液中加入与药物同体积的PBS,确保加入的培养液体积一致。药物作用24h后,使用葡萄糖测定试剂盒,测定细胞上清中的葡萄糖含量。
实验结果:
与模型组比较,芡实种仁多糖能够显著提高胰岛素抵抗HepG2细胞和3T3-L1脂肪细胞的葡萄糖消耗率。在芡实种仁多糖的浓度为25μg/mL,50μg/mL,100μg/mL,200μg/mL,400μg/mL时,胰岛素抵抗HepG2细胞和3T3-L1脂肪细胞的葡萄糖消耗率分别为102.3%、104.1%、104.5%、106.6%、126.1%和72.35%、88.54%、93.27%、95.26%、100.4%。
Claims (3)
1.一种芡实种仁多糖在制备降血糖保健品或药品中的应用,其特征在于:所述芡实种仁多糖的分子量为8.75ⅹ103Da,单糖组成及摩尔比为葡萄糖醛酸:甘露糖:葡萄糖:半乳糖:阿拉伯糖=0.55:0.6:52.7:1:4.3;
所述芡实种仁多糖的分离提取方法包括如下步骤:
步骤1:分离提取
将成熟的芡实种仁粉碎成粉末,加入蒸馏水超声提取5min,然后于60℃水浴2h,四层纱布过滤,收集上清液,向滤渣中加入蒸馏水重复上述提取过程再次提取,合并上清液;将所得上清液旋蒸浓缩,然后加入无水乙醇4℃下静置沉淀,离心收集沉淀,加水溶解沉淀即得粗多糖水溶液;
步骤2:sevag法脱蛋白
将步骤1获得的粗多糖水溶液、三氯甲烷和正丁醇混合,磁力搅拌2-3h,离心后收集上清液;重复上述处理步骤直至蛋白质完全去除,获得脱蛋白芡实种仁多糖溶液;
步骤3:透析除杂
将步骤2获得的脱蛋白芡实种仁多糖溶液旋蒸浓缩除去有机试剂,使用透析袋流水透析48h,蒸馏水透析24h,再次旋蒸浓缩至浓稠状液体,真空冷冻干燥,即得芡实种仁粗多糖;
步骤4:纯化
将步骤3获得的芡实种仁粗多糖通过SuperdexTM75葡聚糖凝胶柱洗脱分离,使用高效液相色谱跟踪检测分离效果,收集保留时间相同的多糖,浓缩冻干后即得芡实种仁纯多糖;
步骤3中,透析袋的截留分子量为3500Da。
2.根据权利要求1所述的应用,其特征在于:
步骤2中,粗多糖水溶液、三氯甲烷和正丁醇混合的体积比为5:4:1。
3.根据权利要求1所述的应用,其特征在于:
步骤4中,洗脱时所用洗脱液为蒸馏水。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810255095.XA CN108424469B (zh) | 2018-03-23 | 2018-03-23 | 一种芡实种仁多糖及其分离提取方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810255095.XA CN108424469B (zh) | 2018-03-23 | 2018-03-23 | 一种芡实种仁多糖及其分离提取方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108424469A CN108424469A (zh) | 2018-08-21 |
CN108424469B true CN108424469B (zh) | 2020-11-17 |
Family
ID=63159765
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810255095.XA Active CN108424469B (zh) | 2018-03-23 | 2018-03-23 | 一种芡实种仁多糖及其分离提取方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108424469B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110396139A (zh) * | 2018-12-26 | 2019-11-01 | 中郅实业(贵州)有限公司 | 一种利用芡实淀粉生产废液提取芡实有效成分的方法 |
CN115611994B (zh) * | 2022-11-01 | 2023-08-04 | 安徽大学 | 一种睡茄多糖及其制备方法和在降糖中的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103275236A (zh) * | 2013-05-31 | 2013-09-04 | 上海师范大学 | 一种芡实多糖提取物的制备方法及其应用 |
-
2018
- 2018-03-23 CN CN201810255095.XA patent/CN108424469B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103275236A (zh) * | 2013-05-31 | 2013-09-04 | 上海师范大学 | 一种芡实多糖提取物的制备方法及其应用 |
Non-Patent Citations (3)
Title |
---|
"芡实降血糖效果的临床研究";杨秋龙;《中医临床研究》;20150323;第6卷(第34期);第26、29页 * |
"超声波辅助提取芡实多糖条件优化";谢燕娟等;《食品研究与开发》;20100805;第31卷(第8期);第15-18页 * |
谢燕娟等."超声波辅助提取芡实多糖条件优化".《食品研究与开发》.2010,第31卷(第8期), * |
Also Published As
Publication number | Publication date |
---|---|
CN108424469A (zh) | 2018-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109651532B (zh) | 一种铁皮石斛葡甘聚糖 | |
CN109400742B (zh) | 一种齿瓣石斛精制多糖及其制备方法和应用 | |
CN102584963B (zh) | 一种活性灵芝多糖肽对照品、制备方法及应用 | |
CN110128562B (zh) | 一种抗肿瘤补骨脂多糖及其提取分离方法和在制备抗肿瘤药物方面的应用 | |
CN112724184B (zh) | 人参中特有化合物精氨酸双糖苷afg的分离制备方法 | |
CN104592323B (zh) | 一种双水相萃取苹果渣中根皮苷的方法 | |
CN108424469B (zh) | 一种芡实种仁多糖及其分离提取方法和用途 | |
CN107541533A (zh) | 一种药食真菌菌丝多糖多肽免疫增强剂的制备方法 | |
Qiao et al. | Anti-fatigue activity of the polysaccharides isolated from Ribes stenocarpum Maxim | |
CN107281258B (zh) | 一种豆芋叶黄酮类提取物及其制备方法和应用 | |
CN110540603B (zh) | 知母多糖及其制备方法、鉴定方法和应用 | |
CN107056851A (zh) | 一种巴戟天总低聚糖的制备方法 | |
CN109232287A (zh) | 一种枸杞子甜菜碱的分离纯化方法 | |
CN111393537A (zh) | 一种海参中生物活性物质的提取方法 | |
CN109081864A (zh) | 一种山药糖蛋白的提取纯化方法 | |
CN113105567B (zh) | 一种蝉拟青霉甘露聚糖及其制备和用途 | |
CN112794925B (zh) | 一种阳春砂多糖及其制备方法和应用 | |
CN113527411A (zh) | 一种怀山药糖肽的分离纯化方法 | |
CN109876021B (zh) | 富含聚炔类化合物的荷叶离褶伞提取物的制备方法及其降糖用途 | |
CN106916065A (zh) | 从牛蒡根中制备高纯度绿原酸的方法 | |
CN108359021B (zh) | 一种快速制备具有抗病毒和免疫调节活性的亚麻籽多糖的方法 | |
CN106699918B (zh) | 野阳合多糖及其制备方法和应用 | |
CN116120475B (zh) | 一种云莓均一多糖rcp-90-1及其分离纯化方法和作为抗肿瘤药物的应用 | |
CN115558035B (zh) | 一种具有免疫调节活性的天麻多糖 | |
CN113956373B (zh) | 一种裂盖马鞍菌多糖及其分离提取方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |